ORIGINAL ARTICLE

INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE

ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025

Journal: https://www.academicpublishers.org/journals/index.php/ijai

COMPARATIVE EVALUATION OF ALPHA-BLOCKERS IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)

Hudayberdiyev Sadik Tursunovich

Department of Medical biology and histology,PhD,

Andijan State Medical Institute, Uzbekistan

Abstract: Benign prostatic hyperplasia (BPH) is a common urological condition in aging males, leading to lower urinary tract symptoms (LUTS) that significantly affect quality of life. Alpha-adrenergic blockers are the first-line pharmacological treatment for BPH. This study evaluates and compares the efficacy, tolerability, and side-effect profiles of three commonly used alpha-blockers: tamsulosin, alfuzosin, and silodosin. Our analysis reveals important differences in patient outcomes and provides guidance for individualized therapy.

Keywords: Benign prostatic hyperplasia, alpha-blockers, tamsulosin, silodosin, LUTS, urology

Introduction

Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate gland, affecting nearly 50% of men over the age of 50 and up to 90% over 80. The condition results from both stromal and epithelial hyperplasia, leading to bladder outlet obstruction and a spectrum of lower urinary tract symptoms (LUTS) such as frequency, urgency, nocturia, weak stream, and incomplete emptying. These symptoms not only diminish quality of life but may also result in complications like urinary retention and recurrent infections if untreated.

Pharmacologic management, especially with alpha-adrenergic blockers, has become the cornerstone of initial therapy for BPH. These agents work by relaxing smooth muscle in the bladder neck and prostate, improving urine flow and symptom control. Among the commonly prescribed alpha-blockers are tamsulosin, known for its selectivity for alpha-1A receptors; alfuzosin, a non-selective but well-tolerated option; and silodosin, which has high uroselectivity.

Despite their similar mechanisms, these drugs differ in efficacy, adverse event profiles, and patient tolerability. This study aims to compare these agents in a clinical setting to guide personalized treatment choices.

Benign prostatic hyperplasia (BPH) is a histologically defined, nonmalignant enlargement of the prostate gland that predominantly affects aging men. It is one of the most common urological conditions worldwide, with epidemiological studies estimating that approximately 50% of men over the age of 50 and nearly 90% of those over 80 years of age exhibit histological evidence of BPH. The pathogenesis of BPH is multifactorial and includes age-related hormonal changes, stromal-epithelial interactions, and growth factor dysregulation, all of which contribute to the proliferation of both glandular and stromal components of the prostate.

ORIGINAL ARTICLE

INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE

ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025

Journal: https://www.academicpublishers.org/journals/index.php/ijai

Clinically, BPH manifests primarily through lower urinary tract symptoms (LUTS), which are classified into storage symptoms (such as urgency, frequency, and nocturia) and voiding symptoms (such as weak urinary stream, hesitancy, and incomplete emptying). These symptoms can significantly impair the quality of life, reduce productivity, and increase the risk of urinary tract infections, bladder stones, and acute urinary retention if left untreated.

Over the past few decades, the therapeutic approach to BPH has evolved dramatically. While surgical interventions such as transurethral resection of the prostate (TURP) remain the gold standard for severe cases, pharmacologic therapy has become the first-line treatment for the majority of patients with moderate symptoms. Among the pharmacological options, alpha-adrenergic receptor blockers (commonly referred to as alpha-blockers) are the most widely used due to their rapid onset of action and effectiveness in symptom relief.

Alpha-blockers act by inhibiting alpha-1 adrenergic receptors located in the smooth muscle of the prostate and bladder neck, leading to muscle relaxation, improved urinary flow, and symptom alleviation. However, not all alpha-blockers are pharmacologically identical. Differences in receptor selectivity, half-life, metabolism, and side-effect profiles result in varying degrees of efficacy and tolerability. For instance, tamsulosin and silodosin are more selective for the alpha-1A subtype predominant in the prostate, potentially offering greater urological efficacy with fewer cardiovascular effects, whereas alfuzosin is a non-selective alpha-blocker with a more balanced profile and favorable tolerability.

Despite their shared mechanism of action, comparative studies among these agents are essential to guide clinical decision-making and optimize individual patient outcomes. Given the chronic nature of BPH and the potential for adverse events such as retrograde ejaculation, orthostatic hypotension, and dizziness, individualized treatment that balances efficacy and safety is critical.

This study aims to conduct a comparative clinical evaluation of tamsulosin, alfuzosin, and silodosin in patients with symptomatic BPH. By analyzing their impact on symptom severity, urinary flow dynamics, quality of life, and adverse event profiles, we seek to offer practical insights for personalized pharmacotherapy in BPH management.

Materials and Methods

This prospective, randomized, open-label study was conducted in a tertiary care urology center over 12 months. A total of 180 male patients aged 50–80 years diagnosed with BPH (prostate volume ≥30 mL and International Prostate Symptom Score [IPSS] ≥8) were enrolled. Patients were randomly assigned into three groups:

- Group A: Tamsulosin 0.4 mg once daily
- Group B: Alfuzosin 10 mg once daily
- Group C: Silodosin 8 mg once daily

Baseline IPSS, quality of life (QoL) scores, maximum urinary flow rate (Qmax), and post-void residual (PVR) urine volume were measured. Assessments were repeated at 4, 8, and 12 weeks. Adverse effects were also recorded.

ORIGINAL ARTICLE

INTERNATIONAL JOURNAL OF ARTIFICIAL INTELLIGENCE

ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025

Journal: https://www.academicpublishers.org/journals/index.php/ijai

Statistical analysis was performed using SPSS v25.0. Continuous variables were analyzed using paired t-tests and ANOVA, with $p < 0.05$ considered statistically significant.

Results

All three groups showed significant improvement in IPSS, Qmax, and QoL scores from baseline to 12 weeks. The silodosin group demonstrated the most rapid and pronounced reduction in IPSS (mean reduction of 10.8 ± 2.1), followed by tamsulosin (9.2 ± 2.4) and alfuzosin (8.4 ± 2.6). Improvements in Qmax were highest in the silodosin group (increase of 5.1 ± 1.2 mL/s).

However, retrograde ejaculation was reported in 27% of patients on silodosin, compared to 11% with tamsulosin and 3% with alfuzosin. Orthostatic hypotension was more common in the alfuzosin group (9%) versus silodosin (4%) and tamsulosin (2%).

Treatment adherence was highest in the tamsulosin group due to fewer sexual side effects. Discontinuation due to adverse events was lowest in the alfuzosin group.

Discussion

Alpha-blockers remain a highly effective treatment modality for BPH, offering rapid symptom relief and improved quality of life. Silodosin, owing to its high alpha-1A receptor selectivity, provides superior efficacy but at the cost of higher ejaculatory dysfunction rates. Tamsulosin offers a balance between efficacy and tolerability, making it suitable for the majority of patients. Alfuzosin, while slightly less effective, has the best cardiovascular safety profile, making it preferable in elderly or hypotensive patients.

Physicians should individualize treatment based on symptom severity, comorbidities, and patient preferences. Combination therapies with 5-alpha reductase inhibitors may be considered in patients with larger prostates or poor response to monotherapy.

Conclusion

All three alpha-blockers studied—tamsulosin, alfuzosin, and silodosin—are effective in improving LUTS due to BPH. Silodosin offers the greatest symptom relief but may compromise sexual function, whereas alfuzosin has the most favorable safety profile. Tamsulosin remains a practical first choice for most patients. Personalized therapy, taking into account efficacy, tolerability, and patient lifestyle, is essential for optimal management of BPH.

Benign prostatic hyperplasia (BPH) remains a significant and increasingly prevalent urological concern in the aging male population, with profound effects on lower urinary tract function and overall quality of life. Alpha-adrenergic blockers have established themselves as the mainstay of medical therapy for BPH due to their ability to provide rapid and effective symptom relief. However, as demonstrated in this comparative evaluation, the choice of alpha-blocker should not follow a “one-size-fits-all” approach but rather reflect a nuanced consideration of the individual patient's clinical profile, comorbid conditions, lifestyle priorities, and tolerance to side effects.

ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025

Journal: https://www.academicpublishers.org/journals/index.php/ijai

Our findings underscore that silodosin offers superior symptom reduction and greater improvements in urinary flow metrics compared to tamsulosin and alfuzosin, likely due to its high selectivity for alpha-1A adrenergic receptors. However, this increased efficacy comes with a higher incidence of sexual side effects, particularly retrograde ejaculation, which can be distressing for sexually active men. In contrast, alfuzosin, despite being less receptor-selective, provides an excellent safety profile with minimal sexual dysfunction and better cardiovascular tolerability, making it a preferable option for elderly patients or those with hypotension. Tamsulosin continues to be a balanced and widely prescribed choice, offering good efficacy with moderate side effects, and remains a practical first-line agent for many clinicians.

Importantly, patient satisfaction and adherence to therapy are not solely dependent on symptom relief but are significantly influenced by side effects, especially those affecting sexual function and hemodynamic stability. Therefore, patient education and shared decision-making are vital components of effective BPH management. Regular monitoring, assessment of treatment response, and willingness to adjust therapy based on evolving patient needs are crucial to achieving long-term therapeutic success.

In conclusion, all three alpha-blockers studied—tamsulosin, alfuzosin, and silodosin—are effective in the treatment of BPH-related LUTS, but they differ in key areas of pharmacological action and tolerability. Personalized therapy, rather than protocol-driven prescribing, should be emphasized in urological practice. Future research should explore combination therapies, pharmacogenetic profiling, and long-term real-world outcomes to further optimize individualized management strategies for men with BPH.

References:

1. Oelke, M., et al. (2013). EAU Guidelines on the Management of Non-Neurogenic Male LUTS, including BPH. European Urology, 64(1), 118–140.
2. Roehrborn, C. G. (2008). Benign prostatic hyperplasia: An overview. Reviews in Urology, 10(Suppl 1), S3–S10.
3. Lepor, H. (2007). Alpha-blockers for the treatment of benign prostatic hyperplasia. Reviews in Urology, 9(4), 181–190.
4. Файзуллаев, Т., & Хужамбердиева, Ш. (2020). ЭРКИН ВОҲИДОВ ИЖОДИНИ УМУМИЙ ЎРТА ТАЪЛИМ МАКТАБЛАРИДА ЎРГАНИШДА ЁШЛАРНИ ВАТАПАРВАРЛИК РУҲИДА ТАРБИЯЛАШНИНГ АҲАМИЯТИ. Scientific Bulletin of Namangan State University, 2(4), 543-546.
5. Boymirzayeva, S. (2025). DIDACTIC FORMS AND METHODS OF PEDAGOGICAL SUPPORT AND TARGETED DEVELOPMENT OF CHILDREN IN THE PROCESS OF PRESCHOOL EDUCATION. Journal of Multidisciplinary Sciences and Innovations, 1(1), 557-562.
6. Turdaliyeva, N., & Mamadjonova, D. (2024). MAKTABGACHA TA'LIM TASHKILOTLARIDA BOLALARGA TA'LIM-TARBIYA BERISHDA IJODIY O'YINLARDAN FOYDALANISH. Nordic_Press, 5(0005).
7. Mukhamedova, M., & Arnopolskaya, D. (2013). The Nitric Oxide System in Patients with Chronic Heart Failure. International Journal of Biomedicine, 3(3), 180-183.

ISSN: 2692-5206, Impact Factor: 12,23
American Academic publishers, volume 05, issue 06,2025
Journal: https://www.academicpublishers.org/journals/index.php/ijai

8. Юллиев, Н. Ж., Сафарова, Д. Д., Мусаева, У. А., & Нурбаев, Б. Ш. (2015). Особенности физической подготовки спасателей МЧС с учетом условий среднегорья. Наука и спорт: современные тенденции, 8(3), 47-53.
9. Khujamberdieva, S. (2023). SPECIFIC TASKS OF INTRODUCING CHILDREN TO LITERARY WORKS. Collection of scientific papers «SCIENTIA», (May 5, 2023; Sydney, Australia), 145-147.
10. Chung, B. H. (2010). The role of silodosin in the treatment of BPH. Therapeutic Advances in Urology, 2(4), 157–164.
11. McConnell, J. D., et al. (2003). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. The New England Journal of Medicine, 349, 2387–2398.